Research Analysts Offer Predictions for TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Stock analysts at Noble Financial lifted their FY2025 earnings estimates for Tonix Pharmaceuticals in a research report issued on Wednesday, December 17th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($13.84) for the year, up from their previous forecast of ($14.95). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Noble Financial also issued estimates for Tonix Pharmaceuticals’ Q4 2025 earnings at ($3.65) EPS, Q1 2026 earnings at ($2.60) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($1.88) EPS, Q4 2026 earnings at ($1.28) EPS and FY2026 earnings at ($8.01) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Monday, November 10th. The company reported ($3.59) earnings per share for the quarter, hitting analysts’ consensus estimates of ($3.59). Tonix Pharmaceuticals had a negative return on equity of 55.19% and a negative net margin of 963.39%.The firm had revenue of $3.29 million for the quarter, compared to the consensus estimate of $2.30 million.

Other equities analysts also recently issued research reports about the company. Wall Street Zen upgraded Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $70.00.

Tonix Pharmaceuticals Stock Down 1.7%

NASDAQ TNXP opened at $16.78 on Monday. The firm has a market capitalization of $197.62 million, a PE ratio of -0.84 and a beta of 1.82. The stock’s 50 day moving average is $17.76 and its 200 day moving average is $28.99. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $69.97.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $25,000. Ameritas Investment Partners Inc. bought a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals in the third quarter valued at approximately $29,000. Police & Firemen s Retirement System of New Jersey bought a new position in Tonix Pharmaceuticals in the second quarter worth approximately $62,000. Finally, BNP Paribas Financial Markets purchased a new position in Tonix Pharmaceuticals during the 2nd quarter worth $65,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.